SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-23-027345
Filing Date
2023-08-09
Accepted
2023-08-09 16:05:51
Documents
58
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 964218
2 ex31-1.htm EX-31.1 19305
3 ex31-2.htm EX-31.2 19286
4 ex32-1.htm EX-32.1 7401
5 ex32-2.htm EX-32.2 7118
  Complete submission text file 0001493152-23-027345.txt   4330846

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20230630.xsd EX-101.SCH 30291
7 XBRL CALCULATION FILE ltrn-20230630_cal.xml EX-101.CAL 47996
8 XBRL DEFINITION FILE ltrn-20230630_def.xml EX-101.DEF 92188
9 XBRL LABEL FILE ltrn-20230630_lab.xml EX-101.LAB 250035
10 XBRL PRESENTATION FILE ltrn-20230630_pre.xml EX-101.PRE 194248
52 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 665177
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 231155100
SIC: 2834 Pharmaceutical Preparations